Shield Therapeutics (LON:STX) has signed an exclusive agreement worth up to US$63mln for its iron deficiency treatment Feraccru to be sold in China. Chief Executive Carl Sterritt came to talk to us at Proactive London and he couldn't hide his enthusiasm at the deal making it over the line, having worked diligently on it for more than a year. News here on when the drug will go commercial, what the terms of the agreeement are and a whisper on discussions with major US partners too.
The deal with ASK Pharm (Beijing Aosaikang Pharmaceutical), covers China, Hong Kong, Macau and Taiwan and will involve an upfront payment of US$11.4mln and up to US$51.4mln in milestone and royalties.
10 Jan 20